Human Angiotensin II Type 1 Receptor Isoforms Encoded by Messenger RNA Splice Variants Are Functionally Distinct
Mickey M. Martin,
Barry M. Willardson,
Gregory F. Burton,
C. Roger White,
Joseph N. McLaughlin,
Steven M. Bray,
James W. Ogilvie, Jr. and
Terry S. Elton
Department of Chemistry and Biochemistry (M.M.M., B.M.W., J.N.M.,
S.M.B., J.W.O., T.S.E.) Department of Microbiology (G.F.B.)
Brigham Young University Provo, Utah 84602
University of
Alabama at Birmingham Vascular Biology and Hypertension Program
(C.R.W.) Birmingham, Alabama 35294
 |
ABSTRACT
|
---|
Human tissues that express the angiotensin II (Ang
II) type 1 receptor (hAT1R) can synthesize four
distinct alternatively spliced hAT1R mRNA
transcripts. In this study, we show that the relative abundance of
these mRNA transcripts varies widely in human tissues, suggesting that
each splice variant is functionally distinct. Here we demonstrate, for
the first time, that the hAT1R-B mRNA splice
variant encodes a novel long hAT1R isoform
in vivo that has significantly diminished affinity for Ang
II (i.e. >3-fold) when compared with the short
hAT1R isoform (encoded by
hAT1R-A mRNA splice variant). This reduced
agonist affinity caused a significant shift to the right in the
dose-response curve for Ang II-induced inositol trisphosphate
production and Ca2+ mobilization of the long
hAT1R when compared with that of the short
hAT1R. The functional differences between these
isoforms allows Ang II responsiveness to be fine-tuned by regulating
the relative abundance of the long and short
hAT1R isoform expressed in a given human
tissue.
 |
INTRODUCTION
|
---|
The peptide hormone, angiotensin II (Ang II), the biologically
active component of the renin-angiotensin system, regulates a variety
of physiological responses including fluid homeostasis, aldosterone
production, renal function, and contraction of vascular smooth muscle
(1). Additionally, Ang II has been demonstrated to be a
growth-promoting factor in cultured rat vascular smooth muscle cells
(2, 3, 4), renal mesangial cells (5), cardiomyocytes (6), and cardiac
fibroblasts (7). This mitogenic response requires the rapid activation
of one or several mitogen-activated protein kinases including
extracellular signal-regulated kinases 1/2 (ERK 1/2), stress-activated
C-Jun N-terminal kinases, and p38 mitogen-activated protein kinase
(8).
The biological responses to Ang II are mediated by its
interaction with high affinity G protein-coupled receptors (GPCRs)
localized on the surface of target cells (9). Two main Ang II receptor
subtypes, AT1R and AT2R,
have been pharmacologically identified (10). AT1R
activation by Ang II stimulates phosphatidylinositol-specific
phospholipase C, leading to the generation of inositol trisphosphate
and diacylglycerol, which are involved in intracellular
Ca2+ mobilization (11, 12) and protein kinase C
activation (13). AT1R activation by Ang II also
stimulates the ERK 1/2 cascade (14); however, the coupling mechanisms
between the AT1R and the ERK 1/2 cascade are
still incompletely characterized. Recent investigations suggest that
Ang II activates ERK 1/2 through transactivation of tyrosine kinase
receptors, which appears to be mediated by several nonreceptor tyrosine
kinases, including the proline-rich tyrosine kinase 2 (PYK2) and Src
family tyrosine kinases (14, 15, 16, 17, 18, 19, 20, 21). Transactivation results in
Shc-Grb2-SOS complex formation and RAS activation, which in turn
initiates a kinase cascade culminating in ERK 1/2 activation (22, 23).
In contrast, the signaling pathways of the AT2R
are not well defined. Although the exact physiological function of the
AT2R is not clear, studies utilizing vascular
smooth muscle cells (24) or coronary endothelial cells (25) suggest
that the AT2R inhibits proliferation. Thus, the
AT2R may antagonize the growth-promoting effects
of the AT1R.
Recently, our laboratory (26, 27) and others (28, 29) have
demonstrated that the human AT1R
(hAT1R) gene is comprised of at least four exons
and spans greater than 60 kilobases (kb). Exons 1, 2, and 3 have been
presumed to constitute the 5'-untranslated region (UTR) mRNA sequence,
while exon 4 harbors the entire uninterrupted open reading frame, for
the hAT1R. A comparison of several published
hAT1R cDNA sequences revealed that although these
cDNA clones shared identical open reading frames, they differed in
portions of their presumed 5'-UTR (30, 31, 32). These results suggested
that alternative splicing events combine various 5'-UTR exons
(i.e. exons 13) with the same coding region exon
(i.e. exon 4). In support of this hypothesis, our laboratory
demonstrated by 5'-rapid amplification of cDNA ends (RACE) experiments
that four distinct hAT1R mRNA splice variants are
synthesized in human lung tissues (i.e.
hAT1R mRNA transcripts are comprised of exons 1
and 4; exons 1, 3, and 4; exons 1, 2, and 4; or exons 1, 2, 3, and 4)
(26, 27). Sequence analysis has shown that an AUG triplet located in
exon 3 is in frame with the downstream open reading frame located in
exon 4 (29). Therefore, hAT1R mRNA transcripts
containing exons 3 and 4 may encode a novel hAT1R
with an amino-terminal extension of 32 amino acids (long
hAT1R) when compared with the short receptor
encoded by exon 1, 4 hAT1R mRNA.
Curnow et al. (29) have previously demonstrated that the
exon 1,3,4 hAT1R mRNA transcript was expressed in
a number of human tissues. Additionally, they demonstrated that human
kidney 293 cells transfected with an exon
1,3,4/hAT1R expression construct produced a
functional hAT1R (29). Although these
investigators demonstrated that transfected 293 cells express
hAT1Rs, they were unable to determine whether
these cells were actually expressing the long
hAT1R isoform. This is a critical consideration
since the AUG codon harbored in exon 3 is not a consensus Kozak
translation initiation start site (33). Therefore, it is possible that
the hAT1R mRNA exon 1,3,4 splice variant does not
encode the long hAT1R, but rather encodes the
short hAT1R, since translation may only be
initiated at the previously characterized AUG start codon harbored in
exon 4 (26, 27, 28, 29). Therefore, the following study was initiated to
determine whether the long hAT1R is actually
expressed in vivo and, if so, to determine whether the long
and short hAT1R isoforms are pharmacologically
and functionally distinct.
 |
RESULTS
|
---|
Tissue Distribution of hAT1R mRNA
Splice Variants
Four known distinct alternatively spliced
hAT1R mRNAs are synthesized from a single
hAT1R gene. These transcripts are comprised of
exons 1 and 4 (hAT1R-A); exons 1, 3, and 4
(hAT1R-B); exons 1, 2, and 4
(hAT1R-C); and exons 1, 2, 3, and 4
(hAT1R-D) (Fig. 1
)
(26, 27). These alternatively spliced mRNAs differ only in the lengths
of their 5'-UTR encoded by exons 1, 2, and 3 while exon 4 harbors the
open reading frame for the hAT1R. To determine
the relative abundance of each hAT1R mRNA splice
variant, total RNA was isolated from various human tissues and
subjected to RT-PCR analysis as described in Materials and
Methods. A hAT1R-specific amplimer set was
used that allowed for the simultaneous amplification of all four
endogenous hAT1R transcripts. To directly compare
the relative abundance of the hAT1R mRNA splice
variants, RT-PCR reactions were terminated and the products quantified
when the samples were in the linear range of amplification. As shown in
Fig. 2
, the hAT1R
PCR products remain in the linear range for only a limited number of
cycles (i.e. human adrenal, 34 cycles; kidney, 34 cycles;
and placenta, 30 cycles). Additionally, the results in Fig. 2
clearly
demonstrate that all four hAT1R splice variants
are expressed in the human tissues investigated; however, each is
expressed in dramatically distinct quantities, relative to one another,
within a given tissue. The relative quantitation of the RT-PCR
experiments are summarized in Table 1
.
These results suggest that each alternatively spliced
hAT1R mRNA may be functionally distinct since
they are differentially expressed in these tissues.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 1. A Schematic Representation of the Four
hAT1R mRNA Splice Variants
Human lung 5'-RACE-ready cDNA was PCR amplified using an anchor and
hAT1R-specific primers. PCR products were subcloned and
sequenced. Four distinct hAT1R cDNA clones were designated
(hAT1R-A hAT1R-D). Sequence analysis
demonstrated that exons 1, 2, and 3 encode 5'-UTR sequence while exon 4
harbors the entire uninterrupted open reading frame for the
hAT1R. Exon 3 also harbors a putative translational start
site.
|
|

View larger version (50K):
[in this window]
[in a new window]
|
Figure 2. Autoradiograms of RT-PCR Experiments Investigating
the Relative Expression of hAT1R mRNA Splice Variants
Total RNA was isolated from various human tissues and subjected to
RT-PCR analysis as described in Materials and Methods.
The expected sizes of the RT-PCR products were 274 bp (product
comprised of exons 1 and 4), 333 bp (product comprised of exons 1, 3,
and 4), 359 bp (product comprised of exons 1, 2, and 4), and 418 bp
(product comprised of exons 1, 2, 3, and 4), respectively. To visualize
the amplified products, the PCR reactions were spiked with
[ -32P]dCTP. The linear range of amplification is shown
for human adrenal, kidney, and placenta. PCR products were not observed
for non-RT samples (data not shown). Each autoradiogram is
representative of at least three separate experiments.
|
|
View this table:
[in this window]
[in a new window]
|
Table 1. Comparison of the Relative Percent Expression
of the hAT1R mRNA Splice Variants in Various Human
Tissues
|
|
Cell Surface Expression of the Long
hAT1R Isoform
To begin to investigate the potential functional differences
between the hAT1R mRNA splice variants, we have
focused our current study on hAT1R-A mRNA
comprised of exons 1 and 4 and hAT1R-B mRNA
comprised of exons 1, 3, and 4 (Fig. 1
). These mRNAs were chosen for
further investigation since sequence analysis demonstrated that exon 3
harbors an AUG translation initiation start site that is in frame with
the major open reading frame located in exon 4. Therefore, if
hAT1R-B mRNA were to be translated, a long
hAT1R isoform with an amino-terminal extension of
32 amino acids would be synthesized when compared with the short
hAT1R encoded by hAT1R-A
(Fig. 3
) (29).

View larger version (26K):
[in this window]
[in a new window]
|
Figure 3. Putative Amino-Terminal Extension of the Long
hAT1R Isoform Encoded by hAT1R mRNAs Containing
Exon 3
The nonshaded nucleotide sequence of exon 4 and the first seven amino
acids (1 7 labeled in bold type) of the short
hAT1R isoform encoded by this sequence is shown. The
nucleotide sequence of exon 3 is shaded. If translation
is initiated at the AUG codon located in exon 3 (shown in bold
type), a long hAT1R isoform with an amino-terminal
extension of 32 amino acids would be synthesized. The suboptimal Kozak
sequence located in both exons 3 and 4 is designated with a
double underline. The most important positions for
efficient translation are a purine at position 3 and a G at position
+4 where A of the AUG codon is defined as position +1 (33 ).
|
|
One major obstacle to the detection of in vivo GPCR
expression has been the well established inability to produce
antibodies that detect the hAT1R by Western
blotting or immunoprecipitation (29). To circumvent these experimental
shortcomings, the cell surface expression of the long and short
hAT1R isoforms was investigated by flow
cytometric analysis utilizing an antibody that recognizes both isoforms
(anti-long/short hAT1R) or an antibody that
recognizes only the long isoform (anti-long
hAT1R).
To establish the specificity of the antibodies to be used in the flow
cytometric experiments, Western blot analyses were performed using
glutathione-S-transferase (GST) fusions of the long/short
hAT1R sequence (MILNSST... ) or the
long-specific hAT1R sequence (MNHKSTD... )
(see Fig. 3
). The results in Fig. 4
demonstrate that the anti-long/short hAT1R
antibody cross-reacts exclusively with the GST-long/short fusion
protein (lane 3) while the anti-long antibody only recognizes the
GST-long fusion protein (lane 6). These results show that the
antibodies tested specifically recognize the expected epitope.

View larger version (58K):
[in this window]
[in a new window]
|
Figure 4. Western Blot Analysis of GST-hAT1R
Fusion Proteins
Purified GST-long/short hAT1R sequence (MILNSST... ) (10
µg), lanes 1, 3, and 5; and GST-long-specific hAT1R
sequence (MNHKSTD... ) (10 µg), lanes 2, 4, and 6 were resolved by
10% SDS-PAGE and analyzed by Western blot with rabbit preimmune,
anti-long/short or anti-long antiserum. Positions of molecular mass
markers are shown on the left in kilodaltons. The data
are representative of three independent experiments.
|
|
Flow cytometric analysis of Chinese hamster ovary (CHO) cells stably
transfected with the pCR/hAT1R-A construct
(i.e. only the short receptor is synthesized) demonstrated
that they were labeled by the anti-long/short
hAT1R antibody (
76% of transfected CHO cells
labeled positive), whereas these same cells were not labeled when the
anti-long hAT1R antibody was used (Fig. 5A
). These results demonstrate that
pCR/hAT1R-A transfected CHO cells only express
the short hAT1R isoform. Mock transfected CHO
cells were not labeled with either antibody (data not shown).

View larger version (57K):
[in this window]
[in a new window]
|
Figure 5. Surface Expression of Long and Short
hAT1R Isoforms on Transfected CHO or H295-R Cells
The overlay histogram plots show the flow cytometric
analysis of CHO cells stably transfected with pCR/hAT1R-A
(panel A), pCR/hAT1R-B (panel B), or
pCR/hAT1R-mut B (panel C) or human adrenocortical, H295-R
(panel D) cells, respectively. Cells were labeled with anti-long/short
hAT1R (L/S) (histogram outlined in
gray), anti-long hAT1R (L)
(histogram outlined in black), or
preimmune serum (PI) (shaded histogram) antibodies. The
cells were subsequently labeled with fluorescein
isothiocyanate-conjugated second antibody and subjected to flow
cytometric analysis. Anti-long/short hAT1R will label
either receptor isoform whereas anti-long hAT1R will label
only the long receptor isoform. The data are representative of three
independent experiments.
|
|
In contrast, CHO cells stably transfected with the
pCR/hAT1R-B construct (i.e. harbors
potential translation initiation codons in both exons 3 and 4) labeled
positive for the long hAT1R. Approximately 42%
of the CHO cells that were recognized by the long
hAT1R antibody and about 98% of the cells that
were recognized by the long/short hAT1R antibody,
clearly demonstrating that the AUG harbored in exon 3 can indeed
initiate translation in vivo (Fig. 5B
). However, the
hAT1R-B transfected cells were not labeled to the
same extent with each antibody (see Fig. 5B
), suggesting that these
cells were expressing a heterogeneous population of long and short
hAT1R consistent with our hypothesis that the
hAT1R-B mRNA (i.e. exon 1,3,4) is
bicistronic and can initiate translation from the AUG start codon
present in either exon 3 or 4. Thus, these data suggest that both
receptor isoforms can be synthesized from the same mRNA. To test this
hypothesis, the AUG start codon in exon 4 of
pCR/hAT1R-B was mutated to AUA (see
Materials and Methods). This new expression construct was
designated pCR/hAT1R-mut B. As seen in Fig. 5C
, pCR/hAT1R-mut B-transfected CHO cells showed a
significant increase in the number of cells that were recognized by the
long hAT1R antibody (
71%), supporting the
hypothesis that the hAT1R-B mRNA is
bicistronic.
To further investigate whether the long hAT1R
isoform was expressed in vivo, a human adrenocortical
carcinoma-derived (H295-R) cell line that expresses high levels of
hAT1Rs (39) was also subjected to flow cytometric
analysis. Importantly, approximately 42% of H295-R cells labeled
positive for the long hAT1R isoform (Fig. 5D
),
supporting our hypothesis that the start codon harbored in exon 3 can
initiate translation in vivo.
To validate the results obtained from the flow cytometric
experiments, CHO cells were transiently transfected with expression
constructs [pcDNA3/hAT1R (N4, 176, 188D),
pCR/hAT1R-B(N26, 36, 208, 220D), or
pCR/hAT1R/hAT1R-mut B(N26,
36, 208, 220D)] that generate aglycosylated
hAT1Rs in vivo (see Materials
and Methods). Transfected CHO cells were subsequently
photoaffinity labeled with
[125I][Bpa8]Ang II and
analyzed by SDS-PAGE and autoradiography. As shown in Fig. 6
, a radiolabeled protein(s) was
identified (lanes 1, 3, and 5) in transfected CHO cells. The labeling
of the AT1R by the photoreactive analog was
completely abolished by 10 µM Losartan, an
AT1R selective antagonist (lanes 2, 4, and 6),
thereby confirming the specificity and selectivity of the labeling.
Since the expressed hAT1Rs are not glycosylated,
the Mr of long hAT1R (lane
5) and the short hAT1R (lane 1) are clearly
distinguishable, approximately 38 kDa vs. approximately 34
kDa. Importantly, an aglycosylated hAT1R-B mRNA
results in the synthesis of both the long and short
hAT1R isoforms (lane 3), again supporting the
hypothesis that this splice variant is bicistronic.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 6. Photoaffinity Labeling of CHO Cells Expressing
Aglycosylated hAT1R Isoforms
CHO cells were transiently transfected with either
pcDNA3/hAT1R-A(N4, 176, 188D), pCR/hAT1R-B(N26,
36, 208, 220D), or pCR/hAT1R-mut B(N26, 36, 208, 220D) and
subsequently labeled with [125I][Bpa8]Ang
II as described in Materials and Methods. After
photolabeling, cellular proteins were solubilized and resolved by 10%
SDS-PAGE followed by autoradiography. Lanes 1 and 2,
[125I][Bpa8]Ang II-labeled proteins from
CHO cells transfected with pcDNA-3/hAT1R-A(N4, 176, 188D)
(i.e. only the short aglycosylated hAT1R can
be synthesized). Lanes 3 and 4,
[125I][Bpa8]Ang II-labeled proteins from
CHO cells transfected with pCR/hAT1R-B(N26, 36, 208, 220D)
(i.e. both the long and short aglycosylated
hAT1R can be synthesized). Lanes 5 and 6,
[125I][Bpa8]Ang II-labeled proteins from
CHO cells transfected with pCR/hAT1R-mut B(N26, 36, 208,
220D) (i.e. only the long aglycosylated
hAT1R can be synthesized). Lanes 2, 4 and 6, Labeling
reactions were performed in the presence of 10 µM
Losartan, an AT1R selective ligand. Protein standards of
the indicated molecular masses (kilodaltons) were run in parallel.
These results are representative of three separate experiments.
|
|
Binding Properties of the Long and Short
hAT1R Isoforms
To determine the binding affinities of the long and short
hAT1R isoforms, membranes isolated from cells
stably transfected with pCR/hAT1R-A or
pCR/hAT1R-mut B were subjected to radioreceptor
competition binding experiments. The IC50 values
from competition binding experiments are summarized in Table 2
. These results demonstrate that the
long hAT1R has a significantly diminished
affinity for Ang II, and most of the Ang II antagonists investigated,
when compared with the short hAT1R
(IC50, 19.8 ± 2.2 nM and
5.9 ± 0.3 nM, P < 0.001, for Ang II,
respectively). Interestingly, the AT1R-selective
nonpeptide antagonist, Losartan, cannot discriminate between the two
hAT1R isoforms (Table 2
).
View this table:
[in this window]
[in a new window]
|
Table 2. Compared Binding Affinities of Angiotensin
Antagonists for Long or Short hAT1R Isoforms Expressed in
CHO Cells
|
|
Functional Properties of the Long and Short
hAT1R Isoforms
To begin to assess the functional properties of the long and
short hAT1R with respect to the initiation of
signal transduction pathways, CHO cell lines stably expressing
approximately the same number of receptor (i.e. CHO/long/no.
95, 2,000 fmol/mg vs. CHO/short/no. 151, 1,800 fmol/mg,
respectively) were used. Since AT1R activation by
Ang II stimulates phosphatidylinositol-specific phospholipase C, we
investigated whether Ang II activation of both isoforms stimulated
inositol trisphosphate (IP3) production.
Importantly, activation of either isoform led to a significant increase
in IP3 levels over basal
IP3 production (data not shown). Since binding
studies revealed significant differences in Ang II affinities for the
hAT1R isoforms, a detailed analysis of the dose
dependence of their IP3 signaling responses was
performed. Representative curves for the IP3
responsiveness of hAT1R isoforms are shown in
Fig. 7
. The dose-response curve for Ang
II-induced IP3 production of the long
hAT1R was shifted to the right when compared with
that of the short hAT1R, consistent with the
reduced agonist affinity of this isoform (Fig. 7
). The
EC50 values determined from three separate
experiments for the long and short hAT1Rs were
16.5 ± 5.4 nM and 2.44 ± 1.11
nM (P < 0.001), respectively.
The EC50 values for IP3
responses of long and short hAT1R showed good
correlation with the respective IC50 values for
inhibition of radioligand binding by Ang II (Table 2
). Time course
experiments of Ang II-induced IP3 stimulation
utilizing stably transfected CHO cells demonstrated that at
subsaturating amounts of Ang II, (10-8
M), the rate of IP3
production was significantly less in cells expressing the long
hAT1R isoform (Fig. 8
). These data suggest that although both
receptor isoforms stimulate IP3 production, the
long hAT1R will produce a diminished Ang II
response at low concentrations of Ang II. In contrast, at higher
concentrations of Ang II, the IP3 production
elicited by both receptor isoforms was essentially identical. At
10-6 M Ang II, a decrease
in [IP3] was observed after the initial
response (data not shown). This phenomenon has been previously observed
(40) and is caused, at least in part, by the inactivation of the
receptor. The inactivation mechanism involves receptor phosphorylation,
ß-arrestin binding, and receptor internalization (41). This process
appears to be equivalent in both the long and short
hAT1R isoforms.

View larger version (22K):
[in this window]
[in a new window]
|
Figure 7. Dose-Response Curve for Ang II-Stimulated
Production of IP3 from CHO Cells Expressing Long or Short
hAT1R Isoforms
Increasing concentrations of Ang II were incubated with CHO cells
expressing the long ( ) or short () hAT1R for 15 sec.
IP3 production was measured as described in
Materials and Methods. Percent maximal IP3
responses were calculated from the equation: [([IP3]
[IP3]o)/[IP3]max
[IP3]o)]*100, where
[IP3]o is the [IP3] in the
absence of Ang II and [IP3]max is the
[IP3] concentration at saturating [Ang II].
Lines represent nonlinear least squares fits of the data
to the equation [([IP3]max
[IP3]o)*[Ang II]/(EC50 + [Ang
II])] + [IP3]o. EC50 values
were determined from the data fit. Data points represent means ±
SE of triplicate determinations. A representative example
of three experiments with similar results is shown.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Figure 8. Time Course for Ang II-Stimulated Production of
IP3 from CHO Cells Expressing Long or Short
hAT1R Isoforms
CHO cells expressing the long ( ) or short () hAT1R
were incubated with 10-8 M Ang II at 25 C for
the indicated times. Data are shown as means of triplicate
determinations ± SE.
|
|
Since the generation of IP3 and diacylglycerol
are involved in intracellular Ca2+ mobilization,
Ang II-induced Ca2+ mobilization in the long and
short hAT1R stably expressing CHO cells was also
examined by measuring the changes in intracellular free
Ca2+ using Fura-2 as a Ca2+
indicator. The dose-response curve for Ang II-induced
Ca2+ mobilization of the long
hAT1R was shifted to the right when compared with
that of the short hAT1R, again consistent with
the reduced agonist affinity of this isoform (Fig. 9
). The EC50 values
determined from 10 separate experiments for the long and short
hAT1Rs were 3.2 ± 0.45 nM and
1.0 ± 0.21 nM (P < 0.001),
respectively.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 9. Dose-Response Curve for Ang II-Stimulated
Ca2+ Activation in CHO Cells Expressing Long or Short
hAT1R Isoforms
CHO cells expressing the long ( ) or short () hAT1R
were loaded with Fura-2 as described in Materials and
Methods. The cells were subsequently incubated with increasing
concentrations of Ang II and [Ca2+]i was
determined. Percent maximal [Ca2+]i was
calculated from the equation: [([Ca2+]
[Ca2+]o)/[Ca2+]max
[Ca2+]o)]*100, where
[Ca2+]o is the [Ca2+] in the
absence of Ang II, and [Ca2+]max is the
[Ca2+] concentration at saturating [Ang II]. Lines
represent nonlinear least squares fits of the data to the equation
[([Ca2+]max
[Ca2+]o)*[Ang II]/(EC50 + [Ang
II)] + [Ca2+]o. EC50 values were
determined from the data fit. Data points represent means ±
SE of 10 individual experiments.
|
|
Identical experiments were performed utilizing additional long and
short clonal CHO cell lines expressing approximately 400 fmol/mg
(CHO/long/no. 3 and CHO/short/no. 126) or 1,000 fmol/mg (CHO/long/no.
47 and CHO/short/no. 154) receptor, respectively (data not shown).
Importantly, all of the long hAT1R-expressing
clonal cell lines investigated showed a decreased affinity for Ang II,
and this reduced agonist affinity resulted in a significant shift to
the right in the dose-response curve for Ang II-induced
IP3 production and Ca2+
mobilization when compared with that of the short
hAT1R-expressing clonal cell lines. Taken
together, these results suggest that the observed differences between
the long and short hAT1R isoforms (Table 1
and
Figs. 79

) were not due to clonal variability.
 |
DISCUSSION
|
---|
In the present study, we have investigated the relative
distribution of the four known hAT1R mRNA splice
variants in human tissues by utilizing RT-PCR. Our results demonstrate,
for the first time, that the relative abundance of each transcript
varies widely in human tissues, suggesting that
hAT1R mRNA splice variants may be functionally
distinct (Fig. 2
and Table 1
). Alternative splicing of GPCR pre-mRNA is
a mechanism observed in many receptor subtypes to further increase the
number of receptor isoforms that can be synthesized from a single
receptor gene. For example, within the GPCR superfamily, alternative
splicing may produce structural variation in the amino terminus
[pituitary adenylate cyclase-activating polypeptide (PACAP) receptor
(42)], the third intracellular loop [dopamine
D2 receptor (43)] or the carboxyl terminus [PG
EP3 receptor (44)]. Structural variation produced by alternative
splicing in GPCRs may result in differences in ligand specificity (42),
modes of signal transduction (43, 44), G protein coupling efficiency
(43), and desensitization (44).
We have focused our current study on the potential functional
differences between two of these mRNA splice variants,
hAT1R-A (comprised of exons 1 and 4) and
hAT1R-B (comprised of exons 1, 3, and 4) since
hAT1R mRNAs containing exons 3 and 4 encode a
novel hAT1R with an amino-terminal extension of
32 amino acids (long hAT1R) when compared with
the short hAT1R encoded by mRNA comprised of
exons 1 and 4 (Fig. 3
). According to the scanning model of eukaryotic
translation (33), the 40S ribosomal subunit with its associated factors
engages the mRNA at or near the cap and then scans in a 3'-direction.
Upon encountering the first AUG initiation codon in an optimal context,
the 60S subunit joins the 40S subunit to form a complete 80S ribosome,
and polypeptide synthesis commences. An optimal sequence,
GCCRCCAUGG, for initiator codons has been defined by a
survey of vertebrate mRNAs (33). The most important positions for
efficient translation are a purine at position 3 and a G at position
+4 where A of the AUG codon is defined as position +1 (33). If these
features are absent, the initiation codon is said to be in a suboptimal
context; therefore, the 40S ribosomal complex may skip the first
initiation codon from the 5'-end and begin translation at a subsequent
AUG (45). Alternatively, the suboptimal AUG may be inefficiently
recognized; thus, a fraction of the 40S ribosomal complexes would
initiate translation while another portion of these complexes would
ignore the first AUG and proceed to a subsequent optimal AUG
(i.e. a leaky scanning mechanism). This scenario would
result in two or more proteins being synthesized by the translation of
a single mRNA. The relative abundance of the multiple products would be
determined by the relative strength of the initiation sites.
With respect to the AUG codon harbored in exon 3 of the
hAT1R-B mRNA splice variant, a purine is at
position 3; however, an A is at position +4 (29); thus, this
initiation codon is in a suboptimal context. Our data demonstrate that
although the AUG in exon 3 is in a suboptimal context, translation is
initiated at this start codon in CHO cells stably, or transiently,
transfected with expression constructs that synthesize the
hAT1R-B or hAT1R-mut B
splice variants (Fig. 5
, AC, and Fig. 6
). More importantly, flow
cytometric experiments demonstrated that a nontransfected human
adrenocortical carcinoma-derived cell line, H295-R, expressed the long
hAT1R isoform, suggesting that the long
hAT1R isoform is synthesized in human tissues
from endogenously expressed hAT1R-B mRNA.
Additionally, our flow cytometric and photo cross-linking data suggest
that the hAT1R-B mRNA splice variant is
bicistronic since it encodes both the long and short
hAT1R isoform (Fig. 5
, B and C, and Fig. 6
). The
synthesis of both isoforms by this mRNA may occur through a leaky
scanning mechanism since the AUG codon harbored in exon 3 is in a
suboptimal context or through an internal ribosome entry site.
Competition binding experiments utilizing membranes isolated from CHO
cells transfected with the pCR/hAT1R-B expression
construct always resulted in displacement curves intermediate
(IC50, 12.1 ± 0.9 nM
vs. 19.8 ± 2.2 nM for the long
and 5.9 ± 0.3 nM for the short
hAT1R, data not shown) of CHO cells expressing
homogeneous populations of long or short hAT1R
isoforms, suggesting that the relative abundance of the isoforms being
synthesized from this splice variant is approximately equal.
Additionally, these data also suggest that the Met
Ile mutation
present in the long hAT1R encoded by the
pCR/hAT1R-mut B construct is not responsible for
the decreased affinity for Ang II since shifts in the displacement
curves were also observed with pCR/hAT1R-B
transfected cells (IC50 12.1 ± 0.9
nM vs. 5.9 ± 0.3
nM for the short hAT1R,
data not shown).
The bicistronic nature of the hAT1R-B mRNA splice
variant is significant because it is atypical of eukaryotic transcripts
(46). Polycistronic transcripts are well described in prokaryotes where
they commonly encode proteins involved in the same functional pathway,
thereby constituting an operon (47). Examples of eukaryotic bicistronic
mRNAs are nearly exclusively known for viral systems. However, there
are increasing reports of mammalian bicistronic mRNAs including
molybdopterin synthase subunits MOCO1-A and MOCO1-B (48), osteogenic
growth peptide (49), c-myc (50), fibroblast growth factor-2
(51), SNRPN (small nuclear ribonucleoprotein N) (52), and
CCAAT/enhancer binding protein-
(53). One possible reason for the
development of such gene fusions in mammals might be the colinear
regulation of gene expression and also to produce guaranteed proximity
of interacting proteins. This may be a critical consideration in light
of the recent observations that some GPCRs can undergo homo- and
heterodimerization (54, 55, 56, 57). Therefore, the coexpression of both
hAT1R isoforms may result in a receptor comprised
of a heterodimer that may be functionally distinct from the
hAT1R monomer.
To accurately assess the pharmacological properties of the long and
short hAT1R isoforms, we used expression
constructs that would synthesize homogenous populations of either the
long or short hAT1R isoform. This was
accomplished by mutating the translational start site located in exon 4
of the hAT1R-B mRNA splice variant (see Fig. 3
).
Our binding data, utilizing membranes isolated from CHO cells stably
transfected with pCR/hAT1R-A or
pCR/hAT1R-mut B expression constructs
demonstrated that the long hAT1R isoform has a
diminished affinity for Ang II (>3-fold), when compared with the short
hAT1R isoform (Table 2
). Additionally, the
dose-response curve for Ang II-induced IP3
production and Ca2+ mobilization of the long
hAT1R was shifted to higher Ang II concentration
when compared with that of the short hAT1R,
consistent with the reduced agonist affinity of this isoform (Figs. 7
and 9
). The reduced affinity of the long hAT1R
for Ang II is not due to the mutation of the translational start site
(Met
Ile) located in exon 4, since more dramatic nonconserved amino
acid changes (i.e. Met
Ser or Asp) did not alter the
IC50 of the long isoform for Ang II (data not
shown).
It was recently demonstrated from two complementing, yet independent,
lines of mutagenesis that the binding of Ang II involves a number of
discontinuously located residues in the extracellular domain of the rat
AT1AR sequence, particularly at the N-terminus
adjacent to the first transmembrane domain (TM-I), a tyrosine in
extracellular loop 1, and two neighboring aspartate residues in the
C-terminal part of the third extracellular loop (58). Taken together
with our data, it is reasonable to speculate that the addition of 32
amino acids to the N terminus of the long hAT1R
would interfere with the important Ang II binding site located in the N
terminus of the short hAT1R (i.e.
equivalent to the rat AT1AR), therefore reducing
this isoforms affinity for Ang II. Alternatively, the reduced
affinity for Ang II may result from the N-linked glycosylation of
Asn26 present in the N terminus of the long
hAT1R. Preliminary competition binding
experiments utilizing membranes isolated from CHO cells transfected
with an expression construct which generates a long
hAT1R isoform that cannot be glycosylated at
Asn26 (i.e. Asn was mutated to Gln)
demonstrated an increased affinity for Ang II
(IC50 of 11.9 ± 1.3
nM vs. 19.8 ± 2.2
nM). Thus, these data suggest that glycosylation
of Asn26 can reduce the affinity of the long
hAT1R for Ang II, but glycosylation cannot
entirely account for the decrease in affinity since the short receptor
has an IC50 of 5.9 ± 0.3
nM.
Interestingly, we have also demonstrated that the long and short
hAT1R isoforms bind the nonpeptide
AT1R-specific antagonist, Losartan, with
identical affinities. These results suggest that the Losartan binding
epitopes in the AT1R are distinct from Ang II and
that these contact points are not compromised by the additional 32
amino acids present in the long hAT1R isoform. In
support of this hypothesis, mutagenesis studies demonstrated that
residues located deep within TM-III, IV, VI, and VII, particularly
Asn295 in TM-VII, impaired the binding of
Losartan without affecting Ang II binding (59, 60).
To investigate potential functional differences between the long and
short hAT1R isoforms, several steps in the Ang
II-induced signal transduction pathways were investigated (
Figs. 79

).
Our results suggest that both receptor isoforms can be activated by Ang
II to stimulate IP3 production and mobilize
Ca2+. Importantly, however, the reduced affinity
of the long hAT1R for Ang II leads to significant
decreases in the amount of IP3 and
Ca2+ produced at subsaturating levels of Ang II
(i.e. 10-8
M) (Figs. 7
and 9
). Taken together, our results
clearly demonstrate that dependent upon the concentration of Ang II,
the percentage of the long and short hAT1R
isoforms activated will differ, and therefore the potency of the Ang II
response will vary.
Since the only difference between the hAT1R-A
(encodes the short hAT1R isoform) and the
hAT1R-B (encodes the long
hAT1R isoform) mRNA splice variants is the
presence or absence of exon 3 (Fig. 1
), we computer analyzed this
sequence utilizing the BLAST program (National Center for Biotechnology
Information, Bethesda, MD) to determine whether
AT1R cDNAs cloned from other animal species
(bovine, dog, mouse, pig, rabbit, rat, sheep, and Xenopus)
shared homology with the hAT1R exon 3 mRNA
sequence. Interestingly, none of these AT1R cDNAs
harbored sequences that were homologous to exon 3 (data not shown).
This analysis suggests that the long and short
hAT1R isoforms described in this study may be a
human-specific phenomenon even though AT1R mRNA
splice variants have been described in other species
(61).
In summary, our results support the hypothesis that in human tissues,
Ang II responsiveness can be fine-tuned by regulating the relative
expression of the long and short hAT1R in a given
tissue. Since the short hAT1R has the highest
affinity for Ang II, abnormally high expression of this receptor would
lead to exaggerated Ang II responsiveness. Therefore, aberrant
regulation of the production of hAT1R isoforms
may play a pivotal role in the pathogenesis of hypertension as well as
other cardiovascular disorders such as cardiac hypertrophy,
coronary artery disease, and atherosclerosis.
 |
MATERIALS AND METHODS
|
---|
Materials
Ang I, Ang II, Ang III, and Ang II antagonists were purchased
from Sigma (St. Louis, MO). The AT1R
nonpeptide antagonist, Losartan, was a generous gift from Merck & Co., Inc. (Rahway, NJ). The
L-Bpa8-Ang II was a generous gift
from Dr. Emanuel Escher (University of Sherbrooke, Sherbrooke, Quebec,
Canada). [125I]Ang II,
[125I][Sar1,
Ile8]Ang II, and
[125I][L-Bpa8]Ang II
ligands were iodinated at the Peptide Radioiodination Center
(Washington State University, Pullman, WA). Oligonucleotides were
purchased from Life Technologies, Inc. (Gaithersburg, MD).
The cDNA clone encoding the aglycosylated short
hAT1R (i.e.
pcDNA3/hAT1R-A mut (N4, 176, 188D) was kindly
provided by Dr. Richard Leduc (University of Sherbrooke).
Cell Culture
CHO cells [American Type Culture Collection
(ATCC), Manassas, VA] were grown in DMEM (Life Technologies, Inc.) supplemented with 10% FBS (HyClone Laboratories, Inc. Logan, UT), 80 U/ml penicillin/80 µg/ml
streptomycin (Life Technologies, Inc.), and 0.0175 mg/ml
L-proline (Sigma). Stably transfected CHO cell
lines were propagated in the same medium with 1,000 µg/ml geneticin
(G418, Life Technologies, Inc.). Human adrenocortical
carcinoma-derived (H295-R) cells (ATCC) were maintained in
DMEM/F12 medium supplemented with 5% NuSerum (Collaborative
Biomedical, Becton Dickinson and Co., Bedford, MA)
and ITS supplement (Collaborative Biomedical). Cell lines were
maintained in a humidified atmosphere at 5% CO2
and 37 C.
RT-PCR
Total RNA was isolated from various human tissues obtained from
the Cooperative Human Tissue Network (Cleveland, OH) utilizing
Tri-Reagent (Molecular Research Center, Inc., Cincinnati,
OH). First-strand cDNA synthesis was performed using SuperScript II
Reverse Transcriptase (Life Technologies, Inc.) and random
primers, according to the manufacturers protocol. A sense primer was
synthesized (5'-ACCCGCACCAGCGCAGCCGGCCCTC-3') that corresponded to
hAT1R nucleotide sequence +194 to +219 bp, with
respect to transcription initiation. An antisense primer was
synthesized (5'-CATAGCTGTGTAGACAGCCCATAGTG-3') that corresponded to
nucleotide sequence +709 to +683 bp (i.e. exon 4, see Fig. 1A
). PCR experiments were performed utilizing various human tissue cDNA
templates and the above described amplimer set. The PCR reactions were
spiked with 1 µl of [
-32P]dCTP (10 µCi
of 3,000 Ci/mM). The linear range of amplification for each tissue was
determined by removing 20 µl of the 100 µl reaction volume at
various cycles. The radiolabeled PCR products were separated by 6%
polyacrylamide gel electrophoresis at 250 V for 3 h. The gel was
then transferred to 3 mm paper, dried, and quantified by
phosphorimaging. The expected sizes of the RT-PCR products were 274 bp
(exons 1 and 4), 333 bp (exons 1, 3, and 4), 359 bp (exons 1, 2, and 4)
and 418 bp (exons 1, 2, 3, and 4), respectively.
Generation of hAT1R Expression
Constructs
To amplify alternatively spliced hAT1R
mRNAs, total RNA was isolated from H295-R cells (ATCC)
using Tri-Reagent (Molecular Research Center, Inc.,
Cincinnati, OH) following the manufacturers protocol. First-strand
cDNA synthesis was performed utilizing Superscript II reverse
transcriptase (Life Technologies, Inc.) and oligo
(dT)12-18. PCR experiments
were performed using H295-R cDNA as template and an amplimer set
specific for the hAT1R. The
hAT1R sense primer synthesized
(5'-ACTTCCAGCGCCTGACAGCCAGG-3') corresponded to nucleotide sequence +1
to +23 bp, with respect to transcription initiation. The
hAT1R antisense primer synthesized
(5'-TCACTCAACCTCAAAACATGGTGC-3') corresponded to nucleotide sequence
+1,362 to +1,338 bp, which encompasses the hAT1R
stop codon. The amplified PCR products were subcloned into the
eukaryotic expression vector, pCR3.1 (Invitrogen,
Carlsbad, CA) and sequenced to ensure authenticity and proper
orientation with respect to the cytomegalovirus (CMV) immediate-early
promoter. Two distinct cDNA clones were isolated and characterized that
corresponded to the hAT1R-A (i.e.
comprised of exons 1 and 4) and hAT1R-B
(i.e. comprised of exons 1, 3, and 4) alternatively spliced
mRNA transcripts (Fig. 1
). These expression constructs were designated
pCR/hAT1R-A and
pCR/hAT1R-B. The expression construct designated
pCR/hAT1R-mut B was generated in a cDNA
containing exons 1, 3, and 4 by site-directed mutagenesis of the AUG
translational start codon located in exon 4 to AUA using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA).
Briefly, a forward mutagenic primer
(5'-CAGGTGATCAAAATAATTCTCAACTCT-3') and a complementary
reverse mutagenic primer (5'-AGAGTTGAGAATTATTTTGATCACCTG-3')
were synthesized (the mutant base is shown in bold type) and
used in a PCR experiment containing pCR/hAT1R-B
template. Twelve PCR cycles were performed, and the amplification
reaction was treated with the DpnI restriction enzyme to
eliminate the parental DNA template. Competent XL-1 Blue cells were
then transformed with DpnI-treated DNA and plated on
LB-ampicillin agar plates. Ampicillin-resistant colonies were
subsequently grown, plasmid DNA was isolated, and the G
A mutation
was confirmed by dideoxy chain termination sequencing.
Generation of CHO Cells Stably Expressing the
hAT1R
The eukaryotic expression constructs,
pCR/hAT1R-A, pCR/hAT1R-B,
and pCR/hAT1R-mut B, were individually
transfected into CHO cells by electroporation (400V, 500 µF, 0.4 cm
cuvette). Pure clonal cell lines were selected by the antibiotic, G418
(1000 µg/ml, Life Technologies, Inc.) and purified by
the limited dilution technique (27). These clonal cell lines were
subsequently assayed for hAT1R expression by
[125I][Sar1,Ile8]AngII
radioreceptor binding experiments. CHO cells that were stably
expressing the hAT1R (e.g. 4002,000
fmol/mg protein) were selected for further study. Nontransfected CHO
cells do not express AT1Rs.
Western and Flow Cytometric Analysis of
hAT1R Expression
A peptide was synthesized that corresponded to the first 15
amino acids of the long hAT1R isoform (see Fig. 3
). A cysteine residue was added at the carboxyl end to facilitate
cross-linking of hemocyanin. Rabbits were immunized with this
conjugated peptide using a standard immunization protocol (Genemed
Biotechnologies, Inc., San Francisco, CA). Peptide-specific antibody
(designated anti-long hAT1R) was obtained by
purifying the sera over a long hAT1R-specific
peptide affinity column. Anti-long/short (N10) antibody, synthesized
against the first 10 amino acids of the short
hAT1R, was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The anti-long/short
hAT1R antibody will react with both the long and
short hAT1R since this amino acid sequence is
present in either receptor.
Western blot analysis was performed utilizing GST-long/short or
GST-long hAT1R fusion proteins. These GST fusion
proteins were generated by subcloning PCR products corresponding to the
first 32 amino acids of the long hAT1R or short
hAT1R into the pGEX-4T-3 vector (Amersham Pharmacia Biotech, Piscataway, NJ). The new constructs were
sequenced to ensure that the hAT1R fusion
proteins were in frame with the GST. The GST fusion proteins were
overexpressed in BL-21 DE3 bacteria, induced with 0.1 mM
isopropyl-ß-D-thio galactopyranoside
(Calbiochem), and purified utilizing glutathione agarose
(Sigma), eluting with 10 mM reduced
glutathione in 100 mM Tris, pH 8.0, on a Biological
chromatography system (Bio-Rad Laboratories, Inc.
Hercules, CA). Purified GST-long/hAT1R N terminus
(1 µg) and GST-short hAT1R N terminus (1 µg)
were subjected to SDS-PAGE and transferred to nitrocellulose membranes.
Membranes were blocked by incubation for 3060 min in 50
mM Tris, pH 7.6, 150 mM NaCl, 1% Tween-20
(TBS-T) with 5% (wt/vol) nonfat dry milk. Blots were incubated
overnight at 4 C in primary antibody (1:1,000) in TBS-T with 5% milk.
The membranes were then washed and incubated with a horseradish
peroxidase-conjugated goat antirabbit secondary antibody at 1:1,000
dilution in TBS-T. Blots were developed utilizing ECL Western detection
system (Amersham Pharmacia Biotech).
CHO cells (1 x 106) stably transfected with
either pCR/hAT1R-A,
pCR/hAT1R-B, pCR/hAT1R-mut
B, or H295-R cells were subjected to flow cytometric analysis. Cells
(1 x 106) were washed and labeled with
either anti-long or anti-long/short hAT1R
antibodies or preimmune serum for 30 min at 4 C. Cells were then washed
with PBS and incubated with 50 µl of a 1:35 dilution [complete
RPMI-1640 (Life Technologies, Inc.) was used as the
diluent] of fluorescein isothiocyanate-conjugated donkey antirabbit
antibody (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) for 30 min at 4 C. Cells were again washed and resuspended
in 1 ml PBS and subsequently analyzed on a Coulter EPICS-XL cytometer
(Coulter Corp., Hialeah, FL) equipped with System II software.
Immediately before examination, 10 µl propidium iodide solution were
added to each tube to allow discrimination of dead cells. Control
experiments were performed as described above utilizing
mock-transfected CHO cells.
Construction of hAT1R Glycosylation
Mutants and Photoaffinity Labeling
The three N-glycosylation sites (N4, 176, and 188) present in
the short hAT1R were previously modified (N
D)
by site-directed mutagenesis and functionally characterized by Lanctot
et al. (35). These investigators designated their expression
construct pcDNA3/hAT1R(N4, 176, 188D). For ease
of discussion in this manuscript, we have renamed this construct
pcDNA3/hAT1R-A(N4, 176, 188D). To generate a long
aglycosylated hAT1R, the
pCR/hAT1R-B and
pCR/hAT1R-mut B expression constructs were used
as template, and the N-glycosylation sites were mutated as previously
described (35). Since the long hAT1R harbors one
additional N-glycosylation site (N-26) in the amino-terminal extension,
this site was also modified N
D. Due to the fact that the long
hAT1R has the amino-terminal extension, the
designation of the mutated Asn residues (N26, 36, 208, 220D) is
different than those of the short hAT1R even
though the same Asn residues are mutated. The new mutant expression
constructs have been designated pCR/hAT1R-B(N26,
36, 208, 220D) and pCR/hAT1R-mut B(N26, 36, 208,
220D).
CHO cells were transiently transfected with either
pcDNA3/hAT1R-A(N4, 176, 188D),
pCR/hAT1R-B(N26, 36, 208, 220D), or
pCR/hAT1R-mut B(N26, 36, 208, 220D) and the cells
were subsequently photolabeled as previously described (35, 36).
Briefly, cells were incubated with 5 nM
[125I][L-Bpa8]Ang
II in the presence or absence of 10 µM Losartan (an
AT1R-selective nonpeptide analog) in 1 ml of
medium containing 25 mM Tris-HCl (pH 7.4), 100
mM NaCl, 5 mM MgCl2, and
0.1% BSA. After 1 h incubation at room temperature, cells were
washed twice with PBS and irradiated for 60 min at 0 C under filtered
UV light (365 nm). Labeled cells were then solubilized in 150 µl of
medium containing 50 mM Tris-HCl (pH 7.4), 1% NP-40, 150
mM NaCl, and 1 mM phenylmethylsulfonyl fluoride
(PMSF). The supernatant was mixed with an equal volume of 2x Laemmli
solution and incubated for 60 min at 37 C followed by electrophoresis
on a 10% polyacrylamide gel at 200 V. Gels were dried under vacuum and
subjected to autoradiography.
Ang II Binding to CHO Cell Membranes
Membranes were isolated from CHO cells stably expressing the
hAT1R isoforms as previously described (37).
Membrane pellets were resuspended in binding buffer (i.e.
PBS containing 100 µg/ml PMSF) and protein concentration was
determined. Competition binding experiments were performed utilizing
2030 µg of membrane protein samples incubated with 0.5
nM
[125I][Sar1,
Ile8]Ang II and increasing concentrations
(10-11 to 10-5
M) of various angiotensin antagonists as
indicated. These experiments were conducted at 25 C for 60 min in a 300
µl total volume of PBS, 0.5% BSA, 100 µg/ml PMSF, 1 µg/ml
leupeptin, and 1 µg/ml aprotinin. The membrane-bound radioligand was
separated from the free radioligand by filtration over glass filters
(GF/B) using a cell harvester (Brandel, Inc., Gaithersburg, MD), and
radioactivity was measured by
-spectrometry. The
IC50 values of the displacement curves were
estimated by nonlinear least squares curve fitting using the computer
program Kaleidagraph (Synergy Software, Reading, PA).
Inositol Trisphosphate Determination
CHO cells stably expressing the long or short
hAT1R isoforms were seeded in six-well plates and
grown to 8090% confluence (2436 h). Cells were washed and
incubated for 72 h in serum-free medium and treated with
increasing concentrations of Ang II as indicated for 15 sec in 600 µl
of serum-free medium. For time course experiments, cells were incubated
0120 sec at the Ang II concentrations indicated. After exposure to
Ang II, the reaction was stopped by the addition of 120 µl of 100%
ice-cold trichloroacetic acid to the plates. The plates were
immediately placed on ice and cells were harvested by scraping and
transferring to polyethylene tubes. Cell extract was centrifuged for 10
min at 14,000 x g. IP3 levels in
the resulting supernatant were determined using a
[3H]radioreceptor-based kit from NEN Life Science Products-DuPont (Boston, MA) following the
manufacturers protocol.
Measurement of Intracellular Ca2+
Concentration
([Ca2+]i)
[Ca2+]i was
measured using the Ca2+-sensitive dye, Fura-2
(Molecular Probes, Inc., Eugene, OR) (38). CHO cells
expressing either the long or short hAT11R
isoform were grown to confluence (5 x 106
cells) on 100-mm diameter dishes and harvested using HBSS with 2
mM EDTA and 1% BSA. Cells were rinsed once with serum-free
DMEM and incubated for 30 min at 37 C in the same medium with 2
µM Fura-2/AM, which was dissolved in dimethyl sulfoxide.
The resulting Fura-2-loaded cells were washed once with serum-free DMEM
and 1% BSA, and then resuspended in the same medium. Approximately
106 cells/ml were used in each experiment. After
stimulation with increasing concentrations of Ang II, fluorescence was
measured using a spectrofluorimeter (Fluorolog model, Spex Industries,
Edison, NJ) with excitation at 340 and 380 nM and
emission at 500 nM.
 |
ACKNOWLEDGMENTS
|
---|
The authors would like to thank Dr. Daniel Simmons (Brigham
Young University) for his contributions in the preparation of this
manuscript and Drs. Emanuel Escher and Richard Leduc at the University
of Sherbrooke for the [Sar1,
Bpa8]Ang II compound and the
pcDNA/hAT1R (N4, 176, 188D) expression
construct.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Terry S. Elton, Ph.D., Department of Chemistry and Biochemistry, Brigham Young University, C206 Benson Building, P.O. Box 25700, Provo, Utah 84602-5700. E-mail:
terry_elton{at}byu.edu
This work was supported by NIH Research Grant 48848.
Received for publication March 13, 2000.
Revision received May 24, 2000.
Accepted for publication November 1, 2000.
 |
REFERENCES
|
---|
-
Peach MJ, Dostal DE 1990 The angiotensin II receptor and
the actions of angiotensin II. J Cardiovasc Pharmacol 16:525530
-
Geisterfer AAT, Peach MJ, Owens GK 1988 Angiotensin II
induces hypertrophy, not hyperplasia, of cultured rat aortic smooth
muscle cells. Circ Res 62:749756[Abstract]
-
Gibbons GH, Pratt RE, Dzau VJ 1992 Vascular smooth muscle
cell hypertrophy vs. hyperplasia. Autocrine transforming
growth factor-ß1 expression determines growth response to angiotensin
II. J Clin Invest 90:456461[Medline]
-
Weber H, Taylor DS, Molloy CJ 1994 Angiotensin II induces
delayed mitogenesis and cellular proliferation in rat aortic smooth
muscle cells. Correlation with the expression of specific endogenous
growth factors and reversal by suramin. J Clin Invest 93:788798[Medline]
-
Homma T, Akai Y, Burns KD, Harris RC 1992 Activation of S6
kinase by repeated cycles of stretching and relaxation in rat
glomerular mesangial cells. Evidence for involvement of protein kinase
C. J Biol Chem 267:2312923135[Abstract/Free Full Text]
-
Sadoshima J, Izumo S 1993 Molecular characterization of
angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia
of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ
Res 73:413423[Abstract]
-
Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM 1993 Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts.
Circ Res 72:12451254[Abstract]
-
Force T, Bonventre JV 1998 Growth factors and
mitogen-activated protein kinase. Hypertension 31:152161[Abstract/Free Full Text]
-
Mendelsohn FA 1985 Localization and properties of
angiotensin receptors. J Hypertens 3:307316[Medline]
-
Timmermans PBMWM Wong PC, Chiu AT, Herblin WF,
Benfield P, Carini DJ, Lee RJ, Weber RR, Saye JAM, Smith RD 1993 Angiotensin II receptors and angiotensin II receptor antagonists.
Pharmacol Rev 45:205251[Medline]
-
Berridge MJ 1993 Inositol trisphosphate and calcium signaling.
Nature 361:315325[CrossRef][Medline]
-
Marks AR 1992 Calcium channels expressed in vascular smooth
muscle. Circulation 86 [Suppl 6]:III61-III67
-
Nishizuka Y 1988 The molecular heterogeneity of protein kinase
C and its implication for cellular recognition. Nature 351:662665[CrossRef]
-
Duff JL, Berk BC, Corson MA 1992 Angiotensin II stimulates the
pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic
smooth muscle cells. Biochem Biophys Res Commun 188:257264[Medline]
-
Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J 1996 A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP
kinase activation. Nature 383:547550[CrossRef][Medline]
-
Linseman DA, Benjamin CW, Jones DA 1995 Convergence of
angiotensin II and platelet-derived growth factor signaling cascades in
vascular smooth muscle cells. J Biol Chem 270:1256312568[Abstract/Free Full Text]
-
Daub H, Weiss FU, Wallasch C, Ullrich A 1996 Role of
transactivation of the EGF receptor in signalling by G-protein-coupled
receptors. Nature 379:557560[CrossRef][Medline]
-
Eguchi S, Namaguchi K, Iwasaki H, Matsumoto T, Yamakawa T,
Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F,
Inagami T 1998 Calcium-dependent epidermal growth factor receptor
transactivation mediates the angiotensin II-induced mitogen-activated
protein kinase activation in vascular smooth muscle cells. J Biol
Chem 273:88908896[Abstract/Free Full Text]
-
Murasawa S, Mori Y, Nozawa Y, Gotoh N, Shibuya M, Masaki H,
Maruyama K, Tsutsumi Y, Moriguchi Y, Shibazaki Y, Tanaka Y, Iwasaka T,
Inada M, Matsubaa H 1998 Angiotensin II type 1 receptor-induced
extracellular signal-regulated protein kinase activation is mediated by
Ca2+/calmodulin-dependent transactivation of
epidermal growth factor receptor. Circ Res 82:13381348[Abstract/Free Full Text]
-
Eguchi S, Iwasaki H, Inagami T, Numaguchi K, Yamakawa T,
Motley ED, Owada KM, Marumo F, Hirata Y 1999 Involvement of PYK2 in
angiotensin II signaling of vascular smooth muscle cells. Hypertension 33:201206[Abstract/Free Full Text]
-
Sabri A, Govindarajan G, Griffin TM, Byron KL, Samarel AM,
Lucchesi PA 1998 Calcium- and protein kinase C-dependent activation of
the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle.
Circ Res 83:841851[Abstract/Free Full Text]
-
Gutkind JS 1998 The pathways connecting G protein-coupled
receptors to the nucleus through divergent mitogen-activated protein
kinase cascades. J Biol Chem 273:18391842[Free Full Text]
-
Luttrell LM, Daaka Y, Lefkowitz RJ 1999 Regulation of tyrosine
kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 11:177183[CrossRef][Medline]
-
Nakajima M, Hutchinson HG, Fuginaga M, Hayashida W, Morishita
R, Horiuchi M, Pratt RE, Dzau VJ 1995 The angiotensin II type 2 (AT2)
receptor antagonizes the growth effects of the AT1 receptor:
gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92:1066310667[Abstract]
-
Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger
T 1995 The angiotensin AT2-receptor mediates inhibition of cell
proliferation in coronary endothelial cells. J Clin Invest 95:651657[Medline]
-
Su B, Martin MM, Beason KB, Miller PJ, Elton TS 1994 The
genomic organization and functional analysis of the promoter for the
human angiotensin II type 1 receptor. Biochem Biophys Res Commun 204:10391046[CrossRef][Medline]
-
Su B, Martin MM, Elton TS 1996 Human AT1
receptor gene regulation. In: Raizada MK, Phillips MI, Sumners C (eds)
Recent Advances in Cellular and Molecular Aspects of Angiotensin
Receptors. Plenum, New York, pp 1122
-
Guo DF, Furuta H, Mizukoshi M, Inagami T 1994 The genomic
organization of human angiotensin II type 1 receptor. Biochem Biophys
Res Commun 200:313319[CrossRef][Medline]
-
Curnow KM, Pascoe L, Davies E, White PC, Corvol P, Clauser E 1995 Alternatively spliced human type 1 angiotensin II receptor mRNAs
are translated at different efficiencies and encode two receptor
isoforms. Mol Endocrinol 9:12501262[Abstract]
-
Takayanagi R, Ohnaka K, Sakai Y, Nakoo R, Yanose T, Haji M,
Inagami T, Furuta H, Guo D, Nakamuta M, Nowata H 1992 Molecular
cloning, sequence analysis and expression of a cDNA encoding human
type-1 angiotensin II receptor. Biochem Biophys Res Commun 183:910916[Medline]
-
Bergsma D, Ellis C, Kumar C, Griffin E, Stadel J, Alyar N 1992 Cloning and characterization of a human angiotensin II type 1 receptor.
Biochem Biophys Res Commun 183:989995[Medline]
-
Curnow KM, Pascoe L, White PC 1992 Genetic analysis of the
human type-1 angiotensin II receptor. Mol Endocrinol 6:11131118[Abstract]
-
Kozak M 1992 Regulation of translation in eukaryotic systems.
Annu Rev Cell Biol 8:197225[CrossRef]
-
Martin MM, White CR, Li H, Miller PJ, Elton TS 1995 A
functional comparison of the rat type-1 angiotensin II receptors
(AT1AR and AT1BR). Regul
Pept 60:135147[CrossRef][Medline]
-
Laporte SA, Boucard AA, Servant G, Guillemette G, Leduc R,
Escher E 1999 Determination of peptide contact points in the human
angiotensin II type 1 receptor (AT1) with photosensitive analogs of
angiotensin II. Mol Endocrinol 13:578586[Abstract/Free Full Text]
-
Lanctot PM, Leclenc PC, Escher E, Leduc R, Guillemette G 1999 Role of N-glycosylation in the expression and functional properties of
human AT1 receptor. Biochemistry 38:86218627[CrossRef][Medline]
-
Campanile CP, Crane JK, Peach MG, Garrison JC 1982 The hepatic
angiotensin II receptor. I. Characterization of the membrane-binding
site and correlation with physiological response in hepatocytes. J
Biol Chem 257:49514958[Free Full Text]
-
Grynkiewicz G, Poenie M, Tsien RY 1985 A new generation of
Ca2+ indicators with greatly improved
fluorescence properties. J Biol Chem 260:34403450[Abstract]
-
Bird IM, Mason JI, Rainey WE 1994 Regulation of type 1
angiotensin II receptor messenger ribonucleic acid expression in human
adrenocortical carcinoma H295R cells. Endocrinology 134:24682474[Abstract]
-
Bohm SK, Grady EF, Bunnett NW 1997 Regulatory mechanisms that
modulate signalling by G-protein-coupled receptors. Biochem J 322:118[Medline]
-
Ushio-Fukai M, Griendling KK, Akers M, Lyons PR, Alexander RW 1998 Temporal dispersion of activation of phospholipase C-ß1 and -
isoforms by angiotensin II in vascular smooth muscle cells. Role of
q/11,
12, and ß
G protein subunits. J Biol Chem 273:1977219777[Abstract/Free Full Text]
-
Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S,
Spengler D, Bockaert J, Journot L 1996 Alternative splicing in the
N-terminal extracellular domain of the pituitary adenylate
cyclase-activating polypeptide (PACAP) receptor modulates receptor
selectivity and relative potencies of PACAP-27 and PACAP-38 in
phospholipase C activation. J Biol Chem 271:2214622151[Abstract/Free Full Text]
-
Picetti R, Saiardi A, Abdel ST, Bozzi Y, Baik JH, Borrelli E 1997 Dopamine D2 receptors in signal transduction and behavior. Crit
Rev Neurobiol 11:121142[Medline]
-
Pierce KL, Regan JW 1998 Prostanoid receptor heterogeneity
through alternative mRNA splicing. Life Sci 62:14791483[CrossRef][Medline]
-
Gray NK, Wickens M 1998 Control of translation initiation in
animals. Annu Rev Cell Dev Biol 14:399458[CrossRef][Medline]
-
Blumenthal T 1998 Gene clusters and polycistronic
transcription in eukaryotes. Bioessays 20:480487[CrossRef][Medline]
-
Jacob F, Monod J 1961 Genetic regulatory mechanisms in the
synthesis of proteins. J Mol Biol 3:318356
-
Sloan J, Kinghorn JR, Unkles SE 1999 The two subunits of human
molybdopterin synthase: evidence for a bicistronic
messenger RNA with overlapping reading frames. Nucleic Acids Res 27:854858[Abstract/Free Full Text]
-
Bab I, Smith E, Gavish H, Attar-Vamder M, Chorev M, Chen Y,
Muhlrad A, Birnbaum MJ, Stein G, Frenkel B 1999 Biosynthesis of
osteogenic growth peptide via alternative translational initiation at
AUG85 of histone H4 mRNA. J Biol Chem 274:1447414481[Abstract/Free Full Text]
-
Nanbru C, Lafon I, Audigier S, Gersoc M, Vagner S, Huez G,
Prats A 1997 Alternative translation of the proto-oncogene c-myc by an
internal ribosome entry site. J Biol Chem 272:320613[Abstract/Free Full Text]
-
Vagner S, Touriol C, Galy B, Audigier S, Gensac M, Amalric F,
Bayard F, Prats H, Prats A 1996 Translation of CUG- but not
AUG-initiated forms of human fibroblast growth factor 2 is activated in
transformed and stressed cells. J Cell Biol 135:13911402[Abstract]
-
Gray TA, Saitoh S, Nicholls RD 1999 An imprinted, mammalian
bicistronic transcript encodes two independent proteins. Proc Natl Acad
Sci USA 96:56165621[Abstract/Free Full Text]
-
Hsieh C, Xiong W, Xie Q, Rabek JP, Scott SG, An MR, Reisner
PD, Kuninger DT, Papaconstantinou J 1998 Effects of age on the
posttranscriptional regulation of the CCAAT/enhancer binding protein
alpha and CCAAT/enhancer binding protein ß isoform synthesis in
control and LPS-treated livers. Mol Biol Cell 9:14791494[Abstract/Free Full Text]
-
Hebert TS, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret
C, Bouvier M 1996 A peptide derived from a ß2-adrenergic receptor
transmembrane domain inhibits both receptor dimerization and
activation. J Biol Chem 271:1638416392[Abstract/Free Full Text]
-
Ng GYK, ODowd BF, Lee SP, Chung HT, Brann MR, Seeman P,
George SR 1996 Dopamine D2 receptor dimers and receptor-blocking
peptides. Biochem Biophys Res Commun 227:200204[CrossRef][Medline]
-
Romano C, Yang WL, OMalley KL 1996 Metabotropic glutamate
receptor 5 is a disulfide-linked dimer. J Biol Chem 271:2861228616[Abstract/Free Full Text]
-
Pace AJ, Gama L, Breitwieser GE 1999 Dimerization of the
calcium-sensing receptor occurs within the extracellular domain and is
eliminated by Cys
Ser mutations at Cys101 and Cys236. J
Biol Chem 274:1162911634[Abstract/Free Full Text]
-
Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW 1994 Identification of peptide binding residues in the extracellular domains
of the AT1 receptor. J Biol Chem 269:3095330959[Abstract/Free Full Text]
-
Ji H, Leung M, Zhang Y, Catt KJ, Sandberg K 1994 Differential
structural requirements for specific binding of nonpeptide and peptide
antagonists to the AT1 angiotensin receptor. Identification of amino
acid residues that determine binding of the antihypertensive drug
losartan. J Biol Chem 269:1653316536[Abstract/Free Full Text]
-
Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW 1994 Differentiation between binding sites for angiotensin II and nonpeptide
antagonists on the angiotensin II type 1 receptors. Proc Natl Acad Sci
USA 91:70467050[Abstract]
-
Takeuchi K, Alexander RW, Nakamura Y, Tsujino T, Murphy TJ 1993 Molecular structure and transcriptional function of the rat
vascular AT1a angiotensin receptor gene. Circ Res 73:612621[Abstract]